Ministry of Industry, Kovid 19 outbreaks of the private sector and making calls to universities and the Ministry of Health in establishing a science army to develop domestic coronavirus vaccine with routing Nanograf to develop vaccines then in Turkey in late February of the emergence of China Inc. and the vaccination team shared the details of their vaccination studies that they have been conducting for 5 months with Demirören News Agency (DHA) for the first time. With the support of public and private sectors, the vaccine developed by scientists from three universities has also been submitted for voluntary human trials. Middle East Technical University, Ankara University and Gazi University as chemistry of Turkey’s best universities, genetics, biochemistry and medicine in each of the signatories have academics formed 40-person team to important studies, he worked day and night to develop a vaccine Kovid will be 19 to cure, animal and immunity cell completed its experiments. In the vaccine study, which has been applied for the approval of the ethical committee with files and detailed reports containing the study results, human trials will be conducted simultaneously with the monkey trials.
“WE WAKE UP ARTIFICIAL LUNG CELLS SLEEPING FOR 10 YEARS”
The head of the Department of Physiopathology, Department of Internal Medicine, Faculty of Medicine, Ankara University, conducting experiments of lung-specific human immune cells in the local Kovid vaccine team. Dr. Nuray Yazıcıhan explained that the foundations of the study were laid in the laboratories of METU Chemistry Department. “The first formulation of the vaccine was made there and their design was chosen. As I had previously worked on the immune system, we already had certain materials. We had a joint project with Germany about 10 years ago. If this lung cells remain hypoxic without oxygen, We tried an artificial lung model to solve how it would react if it had an infection or if it encountered allergic reactions such as asthma. We had artificially developed the parts of the lungs we call Alveol in a laboratory environment. When we set out for the Kovid vaccine, those models were ready.
He also explains that after working with immune cells that eliminate foreign substances in the body called lung-specific macrophages, they freeze and store them in the nitrogen tank. Dr. “We have awakened these cells, which have been sleeping for about 10 years, and tried to understand the effects of the vaccine we developed on our lungs, both through our artificial alveolar model and these cells. This has enabled us to go very quickly in the study. We have also done cell studies with animal studies.
“WE WILL START THE WAR WHERE IT MEETS VIRUS”
Emphasizing that the developed vaccine is designed to be administered nasally, that is, by the nose, unlike the examples in the world, Prof. Dr. “The nasal vaccines are generally not preferred. But when you think of this virus, the first way of infection is the nasal system. There is a structure that we call mucosa. In fact, it is very critical for our immunity. The critical part that distinguishes our work from its counterparts around the world is about what substances we use and how we administer the vaccine formulation, because the most important point in the vaccine is that you create a correct and strong immune response and do not harm the person you administer the vaccine. “We also worked with human immune cells, which we call lung-specific macrophages. In other words, we conducted not only a uniform cell in the animal, but also a study of both animal work and human immune cells, and therefore we have gained a lot of time to approach the result.”
“ACCORDING TO THE VACCINES IN THE WORLD, OUR VACCINE IS POTENTIAL HIGHER”
Underlining that adjuvants, which are placed as supplements next to immune-stimulating vaccine formulations, ensure that they can direct immunity correctly without excessive response in the body. Dr. “When we look at it from this point of view, I think that we can get positive results in human trials and that our vaccine potential can be higher than other vaccines. I can say that we are at the same point with the international vaccine studies that are currently on the agenda in terms of the success of the results. We have no alternative even as a nasal vaccine. Nazal The vaccine is a difficult vaccine, but on the other hand, its application area is very suitable for combating the virus and it has higher effectiveness compared to different application methods such as injection. Our results in our experimental animals are such. We have completed the rat studies. We have not seen any side effects. Therefore, we can now start monkey studies. We submitted our applications, files and reports to the relevant authorities so that we can proceed to clinical studies, voluntary human trials. If the process continues positively, we are ready for human studies. “
FIRST RESULTS IN ANIMAL EXPERIMENTS
According to the results they obtained in animal experiments, Professor said that they obtained results that the vaccine they developed provided protection for about a year. Dr. “Of course the life expectancy of rats and the life expectancy of humans are very different. Of course, we calculate the duration according to their weekly period. For example, the gestation period in rats is 3 weeks, 9 months in humans. In other words, a 3 week study in them corresponds to our 9 months. When we do dose vaccination, we found that the effect lasts about 2 to 4 weeks, which is roughly one year. This is a very good result. But this is a foresight. We will see the real results when human studies are done. “
“THE FIRST TIME VACCINE WILL SUPPORT THE TREATMENT OF THE TREATMENT”
He pointed out that the immune system in the coronavirus can damage the body as a result of overworking while fighting the virus. Dr. “We see reductions in cells that provide longer-term permanent immunity, which we call lymphocytes at the cellular level, in Kovid. To prevent this, it is important to direct a system called immunomodulation (to regulate the immune system). The aim is to direct the T cells in the immune cells with the vaccine, otherwise these T cells can become a harmful system for the body.If you can direct these T cells correctly, you can fight the disease and make these immune cells remember this war again later. We know the effectiveness of this vaccine in both natural killer cells, T cells and macrophage. In fact, we do not expect a therapeutic effect from vaccines under normal conditions. But this aspect of our vaccine is not so long lasting. It will be in question. the opportunity to use the supportive content of the vaccine in the early stages of the disease in addition to immunotherapy treatments. When we look at the studies in the world, we see that our animal and cell culture results are at a level that can compete with them and that we have developed a vaccine that is at least as effective as them. “
“THE VACCINE FORMULA IS OUT OF THIS LABORATORY”
From METU Chemistry Department, Assoc. Dr. Görkem Günbaş, on the other hand, explained that they set out with the team to contribute to Kovid vaccine studies in the laboratory they set up with the fund they received for another research. “We made more preliminary studies of the vaccine on the basis of ideas. He said, “Can we convince the body to produce a Kovid-specific antibody?”
“IMPROVES IMMUNITY AND NO SIDE EFFECTS”
Assoc. Dr. Molecular Biology Specialist Dr., who worked as a team leader of the biochemistry subgroup in Günbaş’s laboratory. Ahmet Çağlar Özketen, on the list of the World Health Organization, stated that 4 scenarios are ahead for Kovid vaccines, and “The first is weakened virus vaccines, the second is mRNA-based vaccines, the third one is called virus-like particle” and the fourth is called subunit vaxcine. Vaccines that contain certain elements of protein or DNA or RNA fragments of the virus, namely the virus. Ours is in this last group. Subunit vaccines are generally preferred because they have less side effects. The main story here is your adjuvant formulation, namely additives that you add to the vaccine, and since we chose nasal administration, we tried a formula that both enhances immunity and eliminates unwanted side effects. using big d trying to produce products in dosages. According to WHO’s estimation, the vaccine will be released in the middle of 2021, but it may be possible to wait for the vaccine to come to our country for a certain period of time. Therefore, it is very important to switch to domestic vaccine studies, even if it is costly. “
“WE AIM TO PREPARE THE END OF THE YEAR”
Acting as a result of President Recep Tayyip Erdogan’s call to the private sector to support scientific research in the fight against the epidemic, the company explained that Nanografi A.Ş., which is within the body of Ahlatcı Holding, has achieved success in this vaccine study with the unlimited support of the Chairman of the Board of Directors Ahmet Ahlatcı. Dr. Osman Coşkun explained that they have been successful with the biotechnology group about DNA for about 3-4 years and discussed what they can do with Kovid 19 vaccine development with the same team. “We have made academic cooperation with scientists from METU, Ankara University and Gazi University. It is a great advantage that the products and proteins are ready beforehand. As Kovid vaccine, we can say that we have reached the point where all global pharmaceutical companies have reached. We hope to complete this vaccine work by the end of the year. “
PROTECTED WITH PATENTS
Thanks to the R&D work carried out in the light of the protocols and practices recommended by the World Health Organization and international authority institutions (FDA, EMA etc.), if the vaccine enters the clinic, it will be easy to export after the production phase as it also provides the protocols accepted as reference. Providing information about the study, the original materials used throughout the study were protected by patent applications and the articles were prepared by experts to be published in international scientific journals soon. “We will not have any import dependence during the production phase in this completely local and national study. We will produce a vaccine that is completely ours with the materials and proteins used in the study with its patents,” Coşkun said.
SUPPORTED BY MINISTRY OF INDUSTRY AND TECHNOLOGY AND MINISTRY OF HEALTH
Noting that his main interests as a company are nanotechnology and biotechnology. Coşkun said, “When the Kovid pandemic process started in the world in February, we started our initiatives for us to work on this issue with the encouragement of our Ministry of Industry and Technology and with the support of our Minister of Health. We carried out the whole process as confidently as possible. Our center is located in METU Technopolis, we worked with METU academics, especially on genetics, and then we worked with our precious teachers from Ankara University and Gazi University was among them. ‘s happened to us unlimited support. our team all the products in need, whether the world, anywhere in the formed provided the opportunity to provide the fastest way possible. Public as particularly TÜSEB (Turkey Institutes of Health Directorate) and TİTCK (Turkey Pharmaceuticals and Medical Devices Agency) Presidency are very nice to us They guided us to come to this point in a short time. they were instrumental in the “.
Source: STAR.COM.TR by www.star.com.tr.
*The article has been translated based on the content of STAR.COM.TR by www.star.com.tr. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!